The selected financial information should be read in conjunction with the financial statements and accompanying notes included under Item 8, "Financial Statements and Supplementary Data" and Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations."
as of and for the years ended December 31 (in millions, except per share data)
2018
2017
2016
2015
2014
Statement of earnings data
Net revenues
$
32,753
$
28,216
$
25,638
$
22,859
$
19,960
Net earnings
5,687
5,309
5,953
5,144
1,774
Basic earnings per share
$
3.67
$
3.31
$
3.65
$
3.15
$
1.11
Diluted earnings per share
$
3.66
$
3.30
$
3.63
$
3.13
$
1.10
Cash dividends declared per common share
$
3.95
$
2.63
$
2.35
$
2.10
$
1.75
Weighted-average basic shares outstanding
1,541
1,596
1,622
1,625
1,595
Weighted-average diluted shares outstanding
1,546
1,603
1,631
1,637
1,610
Balance sheet data
Total assets (a)(b)
$
59,352
$
70,786
$
66,099
$
53,050
$
27,513
Long-term debt and lease obligations (a)(b)(c)
36,611
36,968
36,465
31,265
14,552
(a)
In May 2015, AbbVie acquired Pharmacyclics for approximately $20.8 billion, including cash consideration of $12.4 billion and equity consideration of approximately 128 million shares of AbbVie common stock valued at $8.4 billion. In connection with the acquisition, AbbVie issued $16.7 billion aggregate principal amount of unsecured senior notes, of which approximately $11.5 billion was used to finance the acquisition and approximately $5.0 billion was used to finance an accelerated share repurchase (ASR) program.
(b)
In June 2016, AbbVie acquired Stemcentrx for approximately $6.4 billion, including cash consideration of $1.9 billion, equity consideration of approximately 62.4 million shares of AbbVie common stock valued at $3.9 billion and contingent consideration of approximately $620 million. In connection with the acquisition, AbbVie issued $7.8 billion aggregate principal amount of unsecured senior notes. Of the $7.7 billion net proceeds, approximately $1.9 billion was used to finance the acquisition, approximately $3.8 billion was used to finance an ASR and approximately $2.0 billion was used to repay the company's outstanding term loan that was due to mature in November 2016. See Note 5 to the Consolidated Financial Statements for information regarding the acquisition of Stemcentrx, Note 9 for information on the senior notes and Note 12 for information on the ASR.
(c)
Includes current portion of both long-term debt and lease obligations.
filings.tools
25